The routes used by antigen-presenting cells (APC) to convert the transmembrane fusion glycoprotein (F) of measles virus (MV) to HLA class I and class II presentable peptides have been examined, using cloned cytotoxic T lymphocytes in functional assays. Presentation by Epstein-Barr virus-transformed B lymphoblastoid cell lines was achieved using live virus, ultraviolet light-inactivated virus, and purified MV-F delivered either as such or incorporated in immunostimulating complexes (MV-F-ISCOM). Only live virus and MV-F-ISCOM allow presentation by class I molecules, while all antigen preparations permit class II-restricted presentation. We observe presentation of MV-F from live virus and as MV-F-ISCOM by class II molecules in a fashion that is not perturbed by chloroquine. Our studies visualize novel presentation pathways of type I transmembrane proteins.

, , , , , , , , , , , , , , , ,
The Journal of Experimental Medicine
Erasmus MC: University Medical Center Rotterdam

van Binnendijk, R.S, van Baalen, C.A, Poelen, M.C.M, de Vries, P, Boes, J, Cerundolo, V, … Uytdehaag, F.G.C.M. (1992). Measles virus transmembrane fusion protein synthesized de novo or presented in iscom is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. The Journal of Experimental Medicine, 176, 119–128. Retrieved from